╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ History of seizures (this criterion does not apply │ History of seizures (this criterion does not apply │
│ to subjects who have had a single, uncomplicated   │ to subjects who have had a single, uncomplicated   │
│ febrile convulsion in the past) or neurological    │ febrile convulsion in the past) or neurological    │
│ disease                                            │ disease.                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A family history of congenital or hereditary       │ A family history of congenital or hereditary       │
│ immunodeficiency                                   │ immunodeficiency.                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any investigational or non-registered       │ Use of any investigational or non-registered       │
│ product (drug or vaccine) other than the study     │ product (drug or vaccine) other than the study     │
│ vaccine(s) within 30 days preceding the first dose │ vaccine(s) within 30 days preceding the first dose │
│ of study vaccine, or planned use during the study  │ of study vaccine, or planned use during the study  │
│ period                                             │ period                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Planned administration/ administration of a        │ Planned administration/ administration of a        │
│ vaccine not foreseen by the study protocol during  │ vaccine not foreseen by the study protocol during  │
│ the period starting one month before each dose of  │ the period starting one month before each dose of  │
│ vaccine(s) and ending 7 days after dose 1 and dose │ vaccine(s) and ending 7 days after dose 1 and dose │
│ 2 or 1 month after dose 3                          │ 2 or 1 month after dose 3.                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic administration (defined as more than 14    │ Chronic administration (defined as more than 14    │
│ days) of immunosuppressants or other immune-       │ days) of immunosuppressants or other immune-       │
│ modifying drugs within six months prior to the     │ modifying drugs within six months prior to the     │
│ first vaccine dose                                 │ first vaccine dose.                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Administration of immunoglobulins and/or any blood │ Administration of immunoglobulins and/or any blood │
│ products since birth or planned administration     │ products since birth or planned administration     │
│ during the active phase of the study               │ during the active phase of the study.              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any confirmed or suspected immunosuppressive or    │ Any confirmed or suspected immunosuppressive or    │
│ immunodeficient condition based on medical history │ immunodeficient condition based on medical history │
│ and physical                                       │ and physical                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major congenital defects or serious chronic        │ Major congenital defects or serious chronic        │
│ illness                                            │ illness.                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of allergic disease or reactions likely to │ History of allergic disease or reactions likely to │
│ be exacerbated by any component of the vaccines    │ be exacerbated by any component of the vaccines.   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute disease at the time of enrolment             │ Acute disease at the time of enrolment             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous vaccination against diphtheria, tetanus,  │ Previous vaccination against diphtheria, tetanus,  │
│ pertussis, polio, hepatitis B, Haemophilus         │ pertussis, polio, hepatitis B, Haemophilus         │
│ influenzae type b, and/or S. pneumoniae with the   │ influenzae type b, and/or S. pneumoniae with the   │
│ exception of vaccines where the first dose can be  │ exception of vaccines where the first dose can be  │
│ given within the first two weeks of life according │ given within the first two weeks of life according │
│ to the national recommendations                    │ to the national recommendations                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of or intercurrent diphtheria, tetanus,    │ History of or intercurrent diphtheria, tetanus,    │
│ pertussis, hepatitis B, polio, and Haemophilus     │ pertussis, hepatitis B, polio, and Haemophilus     │
│ influenzae type b diseases                         │ influenzae type b diseases.                        │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛